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Background: On average 12% of the population worldwide suffer from acute or chronic 
constipation. Pathological intestine alterations, an unhealthy diet with reduced liquid intake, and 
little exercise are potential reasons. Often the motility of the intestine is disturbed. Changing 
nutrition habits or lifestyle is not always successful. In such cases, laxatives containing macrogol 
and inulin are highly effective.
Methodology: The efficacy and tolerability of Laxatan® Granulat, a laxative containing 
macrogol, inulin, and mineral salts, was assessed in a drug-monitoring study of 105 patients 
for four weeks.
Results: At the end of this study, a highly significant reduction of the constipation symptoms in 
98.1% of the patients was observed. No adverse events were reported during this drug-monitoring 
study. The overall efficacy was rated as being “very good” or “good” for 96% and the overall 
tolerability was rated as being “very good” or “good” for 99% of patients.
Conclusion: The combination of macrogol, inulin, and mineral salts is highly effective in the 
treatment of chronic constipation. Due to its prebiotic activity, inulin probably leads to prolif-
eration of lactic acid-producing bacteria. The lowered pH and increased water content probably 
increases the peristaltic action and therefore reduces constipation.
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Introduction
Constipation is defined by infrequent bowel movements, typically only every three 
to four days a week, difficulties during defecation, and is associated with hard stool, 
pain, strong pressing, and the sensation of incomplete bowel evacuation. When these 
symptoms last for more than three months, the condition is called chronic constipation. 
The reasons for constipation are manifold. In some cases it is caused by a low fiber 
diet, dehydration, or a lack of exercise. Other reasons are intestinal disorders, treatment 
with medication, or disturbances in the water and electrolyte balance. Changing 
nutrition habits, such as a high fiber diet and higher liquid intake, or a change of the 
lifestyle such as an increased level of exercises are not always effective.1,2 In these cases 
laxatives are useful. However, long-term administration of pharmaceutical laxatives 
could result in habituation and a reduced efficacy of the laxative. Laxatives contain-
ing macrogol and inulin can be used over a long time without causing habituation. 
Macrogol consists of polyethylene glycol (PEG). PEG is a nontoxic and highly 
soluble component, which is not absorbed by the gastrointestinal tract.3,4 PEG acts 
as an osmotic agent by increasing fecal water content.5 The increased stool volume 
dilates the bowel wall and triggers the defecation reflex. The efficacy and safety has Clinical and Experimental Gastroenterology 2009:2 96
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been shown in several clinical studies.6–8 PEG has been 
accepted as a substance generally recognized as safe (GRAS) 
by the US Food and Drug Administration (FDA). Inulin 
has no or only minor laxative properties, but pronounced 
prebiotic activity.9,10 In contrast to probiotics, which are 
defined as viable microbials, prebiotics are nondigestible for 
humans, but selectively stimulate the growth and activity of 
bifidobacteria and lactobacilli.11 These microorganisms are 
well known because of their positive effect on the intestinal 
health by producing lactic acid which lowers the pH in the 
colon and leads to an increased peristaltic activity.12
The primary objective of this drug-monitoring study 
was to assess the efficacy and tolerability of Laxatan® 
Granulat, a combination of macrogol, inulin, and mineral 
salts, in symptoms of chronic constipation. To the best of our 
knowledge, this is the first study to investigate the effect of a 
combination of macrogol and the prebiotic inulin on patients 
with chronic constipation.
Patients and methods
In total 105 patients (86 women; 19 men) with chronic 
constipation and at least three constipation symptoms of 
moderate intensity were enrolled into this drug monitoring 
study. Additionally, all patients were at least 18 years old and 
long-term user of laxatives. Exclusion criteria consisted of 
anaphylaxis against one of the ingredients of the medication, 
simultaneous intake of other laxatives, dubious pain in the 
abdominal cavity, possibility of intestinal perforation, intestinal 
obstruction, inflammatory colon disease (such as Crohn’s 
disease, colitis ulcerosa), acute toxic megacolon, serious organ 
or systemic disease, alcohol abuse, drug or medication abuse, 
or pregnancy or lactation. The patients had an average age of 
64.3 years (22 to 94 years), an average height of 164.7 cm 
(141 to 187 cm), and an average weight of 74.8 kg (50 to 
162 kg). During the first two weeks the patients took 2 × 2 
packages of Laxatan® Granulat (dissolved in 125 ml water) 
daily. In the following two weeks the dosage was reduced to 
2 × 1 package of Laxatan® Granulat per day. One package 
of Laxatan® Granulat contains 13.125 g macrogol 4000, 
0.25 g magnesium citrate, 0.125 g calcium citrate, 0.015 g 
potassium chloride, and 1.0 g inulin. During the course of the 
study, a total of three examinations were performed for each 
patient: a baseline assessment at the start of the study, a control 
examination after about two weeks, and a final examination 
after about four weeks at the end of the study.
At each examination, the following constipation symptoms 
were rated by means of a four-point rating scale: infrequent 
defecation, firm stool, painful defecation, strong pressing 
during defecation, stomachache, sensation of fullness, 
and flatulence. Rome criteria were not used to diagnose 
constipation. At the end of the study the sum score of all 
constipation symptoms was calculated for each examination 
and the change of the sum score at study end compared to 
baseline was assessed. The sum score was calculated based on 
the average score of each symptom (0 to 3 points) and could 
reach a value between 0 and 21 for all seven symptoms. The 
efficacy criteria were the decrease of the sum score for the 
constipation symptoms and a global assessment of the efficacy 
conducted by the physicians and patients at the end of the 
study. The tolerability was evaluated based on the occurrence 
of adverse events and by a global assessment of the tolerability 
by the physicians and patients at the end of therapy.
The study was performed according to the recommendations 
of German Federal Institute for Drugs and Medical Devices 
(BfArM), The German Society for Phytotherapy (GPHY), as 
well as the German Society for Medical Computer Science 
Biometry and Epidemiology (GMDS).13–15
Statistical analysis
The results of this study are presented descriptively, with 
efficacy evaluated by means of a pretreatment versus 
post-treatment comparison. A Wilcoxon test for paired values 
was used for changes in the sum score of the constipation 
symptoms and Pearson’s chi-squared test was used to 
calculate the level of significance.
Results
Data were analyzed for all 105 patients. To evaluate the 
efficacy of the Laxatan® Granulat, the seven constipation 
symptoms (infrequent defecation, firm stool, painful defeca-
tion, strong pressing during defecation, stomachache, feeling 
of fullness, flatulence) were assessed at three examinations 
by the physician. Each constipation symptom was rated on 
a four-point rating scale (0 = none, 1 = minor, 2 = moderate, 
and 3 = severe) resulting in an average score for each symp-
tom at each examination between 0 and 3. The frequency 
distribution of the seven constipation symptoms at each 
examination is summarized in Table 1.
For all examined symptoms an improvement could be 
demonstrated by a comparison before and after treatment.
Before treatment
Infrequent defecation
At the first examination, all patients (100%) complained 
of moderate or severe infrequent defecation. By the end 
of the therapy (third examination) 82.7% showed no or Clinical and Experimental Gastroenterology 2009:2 97
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minor complaints of this symptom, and only 12.4% of the 
patients still suffered from moderate or strong infrequent 
defecation.
Firm stool
At the beginning of therapy, 104 patients were afflicted by 
firm stool (26.7% moderate, 72.4% severe). After about two 
weeks (second examination), 73.3% were either free of this 
symptom or had only minor complaints. At the end of the 
study only one patient had severe problems with firm stool.
Painful defecation
Moderate or severe pain during defecation was reported by 
69.5% of patients at the first examination. At the end of the 
observation, 91.4% of patients were either free of pain or 
reported tolerable (minor) pain during defecation.
Strong pressing during defecation
Like all other symptoms the strong pressing during defecation 
symptom was significantly reduced from the first to third 
examinations. At the beginning of the study, defecation was 
associated with severe or moderate pressing for 89.5% of 
the patients. Only 14.3% rated this symptom as severe or 
moderate after about four weeks at the third examination.
Stomachache
In 43.3% of patients, constipation was associated with 
moderate or severe stomachache. At the end of the study, 
68 of 105 patients (64%) were free of stomachache and none 
of the patients complained about severe stomachache.
Feeling of fullness
At the first examination, 77.2% of the patients complained 
about a moderate or severe feeling of fullness. By the end 
of the therapy (third examination), 79.0% had no or minor 
complaints of this symptom and only 20.9% still suffered 
from moderate or strong feeling of fullness.
Flatulence
Flatulence was reported as moderate or severe by 66.7% of 
the patients at the first examination. At the end of the study, 
26 of 105 patients (24.8%) still suffered from moderate or 
severe flatulence. 52.4% complained about minor flatulence 
and 22.9% of the patients were symptom free.
Table 1 Frequency distribution of constipation symptoms at the first, second, and third examinations
Symptoms Examination N Assessment of intensity
None Minor Moderate Severe
Patients [%] Patients [%] Patients [%] Patients [%]
Infrequent defecation 1 105 0 0 0 0 44 41.9 61 58.1
2 105 31 29.5 45 42.9 27 25.7 2 1.9
3 105 43 41.0 49 46.7 11 10.5 2 1.9
Firm stool 1 105 0 0 1 1.0 28 26.7 76 72.4
2 105 37 35.2 40 38.1 26 24.8 2 1.9
3 105 48 45.7 48 45.7 8 7.6 1 1.0
Painful defecation 1 105 19 18.1 13 12.4 44 41.9 29 27.6
2 105 58 55.2 31 29.5 13 12.4 3 2.9
3 105 73 69.5 23 21.9 8 7.6 1 1.0
Strong pressing 1 105 4 3.8 7 6.7 40 38.1 54 51.4
2 105 42 40.0 36 34.3 22 21.0 5 4.8
3 105 60 57.1 30 28.6 13 12.4 2 1.9
Stomachache 1 104 38 36.5 21 20.2 34 32.7 11 10.6
2 105 64 61.0 29 27.6 11 10.5 1 1.0
3 105 68 64.8 30 28.6 7 6.7 0 0
Feeling of fullness 1 105 4 3.8 20 19.0 49 46.7 32 30.5
2 105 33 31.4 43 41.0 25 23.8 4 3.8
3 105 48 45.7 35 33.3 20 19.0 2 1.9
Flatulence 1 105 5 4.8 30 28.6 44 41.9 26 24.8
2 105 17 16.2 50 47.6 31 29.5 7 6.7
3 105 24 22.9 55 52.4 22 21.0 4 3.8Clinical and Experimental Gastroenterology 2009:2 98
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After treatment
The improvement of chronic constipation could also be 
demonstrated by the decrease of the average scores of the 
individual constipation symptoms. The decrease of these 
scores is shown in Figure 1.
Infrequent defecation
The average score for the symptom infrequent defecation 
was 2.58 ± 0.5 at the beginning of the therapy and 
dropped down to 0.73 ± 0.73 at the last examination. The 
improvement rate of 71.1% is statistically highly significant 
(P  0.001).
Firm stool
The average score for this symptom was 2.71 ± 0.48 
at the first examination and decreased to 0.64 ± 0.67 at 
the third examination. The improvement rate of 76.4% 
by the end of the study is statistically highly significant 
(P  0.001).
Painful defecation
The average score for painful defecation had a value of 
1.79 ± 1.04 at the beginning of the study and a value 
of 0.40 ± 0.67 by the end of the study. The improvement rate 
of 77.6% is statistically highly significant (P  0.001).
Strong pressing during defecation
The average score for the symptom of strong pressing during 
defecation was 2.37 ± 0.78 at the beginning of the therapy 
and dropped down to 0.59 ± 0.78 at the last examination. 
The improvement rate of 75.1% is statistically highly 
significant (P  0.001).
Stomachache
The average score for this symptom was reduced from 
1.17 ± 1.05 at the first examination to 0.42 ± 0.62 by the 
end of the study. The improvement rate of 64.1% is highly 
statistically highly significant (P  0.001).
Feeling of fullness
The average score for “feeling of fullness” had at the 
beginning of the study a value of 2.04 ± 0.81 which decreased 
to 0.77 ± 0.82 at the last examination. The reduction of 
the symptom by 62.3% is statistically highly significant 
(P  0.001).
Flatulence
The reduction of the average score of this symptom 
was statistically highly significant. The average score 
decreased from 1.87 ± 0.84 at the first examination to 
1.06 ± 0.77 at the third examination, which represents a 
statistically highly significant (P  0.001) improvement 
rate of 43.3%.
Summation of the average scores of the seven individual 
symptoms resulted in the sum score for all symptoms as 
shown in Figure 2. This sum score clearly demonstrates 
a strong reduction of the constipation symptoms between 
the first, second, and third assessment. The value dropped 
from 14.5 ± 2.9 points at the beginning of the study to 
4.6 ± 3.9 points by the end of the study, which represents an 
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improvement rate of 68%. This result was statistically highly 
significant (P  0.001)
Global assessment of efficacy
At the end of the observation period the efficacy of Laxatan® 
Granulat was rated both by the physicians and the patients. 
The categories were “very good”, “good”, “moderate”, and 
“insufficient”. 96.1% of the physicians and the patients rated 
the efficacy as being “very good” or “good”. 91.3% of the 
patients reported that Laxatan® Granulat had a better effect 
than the laxatives used previously.
Global assessment of tolerability
An evaluation of the tolerability of Laxatan® Granulat was 
performed by the patients and the physicians. The product 
was reported as being “very good” or “good” by 98.0% of 
the patients and 99.0% of the physicians, respectively. There 
were no adverse events during the course of the study.
Global assessment of compliance
Compliance was judged by the physicians as being “very 
good” or “good” for 96.1% of patients.
Discussion
The term chronic constipation is used if there is no defecation 
for periods of four days for longer than three months, when 
strong pressure is necessary for defecation and if there 
is a feeling of incomplete defecation. The objective of 
treatment of constipation is the increase in intestinal motility. 
Macrogols are polymeric macromolecules (PEG), which are 
not adsorbed by the digestive system. Due to their osmotic 
activity and the ability to bind water, they hydrate hardened 
stool and increase the stool volume, leading to expansion 
of the intestinal wall. This provokes the defecation reflex.16 
In contrast to lactulose, a commonly used osmotic-acting 
laxative, PEG is more effective17 with fewer side effects. The 
use of lactulose may lead to habituation, which has not been 
observed with PEG.18
The safety and efficacy of PEG preparations in treatment 
of chronic constipation has been shown in several short-19,20 
and long-term clinical studies21–23 and are summarized 
in several reviews.6,24,25 The safety of PEG has also been 
demonstrated in toxicity studies, where PEG neither showed 
mutagenic nor carcinogenic effects.26,27
The efficacy and safety has even been demonstrated in 
children. Eighty-three children received the PEG therapy on 
average for 8.7 months. The medication was well tolerated 
and did not cause major clinical adverse effects.22 The use 
of macrogol is nowadays the first choice for treatment of 
chronic constipation.
However, it has been shown that PEG 4000 may inhibit 
the metabolic activities of the fecal flora.19 Inulin on the 
other hand is a prebiotic. Prebiotics are not laxatives. They 
have a positive influence on the composition of intestinal 
flora and move the bacterial colonies in the direction of the 
desired bifidobacteria and lactobacilli. These bacteria build 
lactic acid and lower the pH in the colon, which increases the 
peristaltic of the intestine.12 Therefore, the new combination 
product of both PEG and inulin will be beneficial for patients 
suffering from constipation.
Conclusion
To our knowledge this is the first drug-monitoring study 
to investigate the efficacy and safety of a combination 
product of macrogol, inulin, and mineral salt in patients 
with chronic constipation. This study has demonstrated 
very good efficacy and safety in the combination product of 
macrogol and inulin. Upon conclusion of the drug-monitoring 
study, 98.1% of the patients showed an improvement of the 
symptoms of chronic constipation. The sum score for the 
constipation symptoms calculated from the average scores 
of the individual symptoms at the conclusion of the study 
(after 32.2 days) showed a statistically highly significant 
(P  0.001) improvement of 68.3% and a clinically relevant 
reduction of the symptoms. The average scores of the 
individual symptoms (infrequent defecation, hard defecation, 
painful defecation, strong pressure necessary for defecation, 
stomachache, feeling of fullness, and flatulence) showed a 
statistically highly significant decrease (P  0.001) between 
the first and third examinations. The improvement rates for 
the individual symptoms lay between 43.3% and 77.6% 
(before/after comparison).
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At the end of the observation period, 96.1% of the 
physicians and patients rated the efficacy of the treatment as 
being “very good” or “good”. 91.3% of the patients stated 
that Laxatan® Granulat had a better effect than the laxative 
used previously.
The tolerability of the product was rated as being “very 
good” or “good” by 98.0% of the patients and 99.0% of 
the physicians, respectively. No adverse events occurred 
during the course of the study. Compliance was judged by 
the physicians as being “very good” or “good” for 96.1% 
of patients.
The results of this drug-monitoring study demonstrate a 
very good efficacy and tolerability of the combination product 
containing macrogol, the prebiotic inulin, and mineral salts 
with statistically highly significant and clinically relevant 
improvements of the symptoms of chronic constipation. We 
have shown that the combination is highly effective. However, 
we don’t know to which extent the individual components 
influence the result. Further double-blind, placebo-controlled 
clinical trials should be performed to distinguish between 
the different components and to confirm these promising 
findings.
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